Epogen IP Fight Ends With Hospira Paying More Than $70M
Hospira Inc. has paid Amgen Inc. more than $70 million for infringing a patent covering its anemia treatment Epogen, after the Federal Circuit refused to grant Hospira any relief from a...To view the full article, register now.
Already a subscriber? Click here to view full article